Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart^® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis

References

• ButlerMForteMLSchwehrNCarpenterAKaneRLDecisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosisComparative Effectiveness Review150
   Google Scholar
• KingwellEMarriottJJJettéNIncidence and prevalence of multiple sclerosis in Europe: a systematic reviewBMC Neurol20131312824070256
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• HansenKSchüsselKKiebleMAdherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort studyPLoS One2015107e013327926214805
   PubMed Web of Science ®Google Scholar
• WongJGomesTMamdaniMMannoMO’ConnorPWAdherence to multiple sclerosis disease-modifying therapies in Ontario is lowCan J Neurol Sci201138342943321515501
   PubMed Web of Science ®Google Scholar
• TanHCaiQAgarwalSStephensonJJKamatSImpact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdv Ther2011281516121153000
   PubMed Web of Science ®Google Scholar
• YermakovSDavisMCalnanMImpact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosisJ Med Econ201518971172025903661
   PubMed Web of Science ®Google Scholar
• DevonshireVLapierreYMacdonellRThe Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosisEur J Neurol2011181697720561039
   PubMed Web of Science ®Google Scholar
• SartoriACarleDFreedmanMSTeriflunomide: a novel oral treatment for relapsing multiple sclerosisExpert Opin Pharmacother20141571019102724742277
   PubMed Web of Science ®Google Scholar
• RemingtonGRodriguezYLoganDWilliamsonCTreadawayKFacilitating medication adherence in patients with multiple sclerosisInt J MS Care2013151364524453761
   PubMedGoogle Scholar
• LugaresiARottoliMRPattiFFostering adherence to injectable disease-modifying therapies in multiple sclerosisExpert Rev Neurother20141491029104225109614
   PubMed Web of Science ®Google Scholar
• CaonCSaundersCSmrtkaJBaxterNShoemakerJInjectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence dataJ Neurosci Nurs2010425 SupplS5S921049828
   PubMed Web of Science ®Google Scholar
• TurnerAPSloanAPKivlahanDRHaselkornJKTelephone counseling and home telehealth monitoring to improve medication adherence: results of a pilot trial among individuals with multiple sclerosisRehabil Psychol201459213614624708232
   PubMed Web of Science ®Google Scholar
• LugaresiARebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherenceExpert Opin Drug Deliv201310227328323252744
   PubMed Web of Science ®Google Scholar
• LugaresiAFlorioCBrescia-MorraVPatient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV studyBMC Neurol201212722390218
   PubMed Web of Science ®Google Scholar
• BayasAOualletJCKallmannBHuppertsRFuldaUMarhardtKSMART study groupAdherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART studyExpert Opin Drug Deliv20151281239125026098143
   PubMed Web of Science ®Google Scholar
• WillisHWebsterJLarkinAMParkesLAn observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection devicePatient Prefer Adherence2014884385124966669
   PubMed Web of Science ®Google Scholar
• LugaresiADe RobertisFClericoMLong-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER studyExpert Opin Drug Deliv201613793193526909646
   PubMed Web of Science ®Google Scholar
• European Medicines AgencySummary of Product Characteristics RebifEMA2009 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdfAccessed April 21, 2017
   Google Scholar
• BruceJMHancockLMLynchSGObjective adherence monitoring in multiple sclerosis: initial validation and association with self-reportMult Scler201016111212019995835
   PubMed Web of Science ®Google Scholar
• GreenlawSMYentzerBAO’NeillJLBalkrishnanRFeldmanSRAssessing adherence to dermatology treatments: a review of self-report and electronic measuresSkin Res Technol201016225325820456106
   PubMed Web of Science ®Google Scholar
• HalpernRAgarwalSDembekCBortonLLopez-BresnahanMComparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysisPatient Prefer Adherence20115738421423591
   PubMed Web of Science ®Google Scholar
• MikolDLopez-BresnahanMTaraskiewiczSChangPRangnowJRebiject Study GroupA randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosisMult Scler200511558559116193898
   PubMed Web of Science ®Google Scholar
• van OnzenoortHAMengerFENeefCParticipation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort studyHypertension201158457357821825228
   PubMed Web of Science ®Google Scholar
• HartAMann-Whitney test is not just a test of medians: differences in spread can be importantBMJ2001323730939139311509435
   PubMed Web of Science ®Google Scholar
• LarsenJStovringHKragstrupJHansenDGCan differences in medical drug compliance between European countries be explained by social factors: analyses based on data from the European Social Survey, round 2BMC Public Health2009914519445714
   PubMed Web of Science ®Google Scholar
• Fernández-FournierMTallón-BarrancoAChamorroBMartínez-SánchezPPuertasIDifferential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferonBMC Neurol20151514126286576
   PubMed Web of Science ®Google Scholar
• DevonshireVArbizuTBorreBPatient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyBMC Neurol2010102820433746
   PubMed Web of Science ®Google Scholar